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Oncolytic viruses exploit tumor-specific cellular changes for selective replication, 
inducing cancer cell death. Our previous research showed that Ras/mitogen-activated 
protein kinase kinase (MEK) downregulation of interferon regulatory factor 1 (IRF1) is a 
major mechanism underlying viral oncolysis. Protein inhibitor of activated STAT 3 
(PIAS3) is known as the E3 ligase of IRF1 sumoylation. The objective of this study was 
to identify if, and how, PIAS3 modulates cellular sensitivity to oncolytic viruses via 
regulation of IRF1. By conducting co-immunoprecipitation, I found that IRF1 has no 
direct interaction with PIAS3 found within HT1080 cells. However, CRISPR knockdown 
of PIAS3 increases IRF1 expression as well as transcription of IRF1-responsive anti-viral 
genes. Furthermore, PIAS3 knockdown HT1080 cells were equally sensitive to viral 
infection as their parent HT1080 cells. Together, these results demonstrate that PIAS3 
does not directly interact with IRF1 but regulates expression and transcriptional activity 
of IRF1. Moreover, as CRISPR knockdown of PIAS3 did not change cellular sensitivity 
to viral infection, IRF1 modulation via PIAS3 does not play very critical roles in host 







Oncolytic viruses selectively kill cancer cells but not normal cells. Our previous research 
has shown that the expression of antiviral protein, interferon regulatory factor 1 (IRF1), 
is suppressed in cancer cells, which increases their susceptibility to oncolytic virus 
infection. The objective of my MSc project was to determine if and how protein inhibitor 
of activated STAT 3 (PIAS3), a known modulator of IRF1, suppresses antiviral functions 
of IRF1 in cancer cells. I found that PIAS3 does not directly interact with IRF1 but 
regulates the expression and transcriptional activity of IRF1 in cancer cells. However, 
IRF1 modulation via PIAS3 is not sufficient to change cellular susceptibility to virus 
infection. These results suggest that PIAS3 is not involved in cellular mechanisms of 












In this thesis, most work was done by the author of the thesis Danyang Xu. The CRISPR 
knockdown clones were generated by Ysabel Meneses, another graduate student of the 
Hirasawa lab, which is described in Chapter 3 part 3. All the other experiments in the 
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1.1 Oncolytic viruses  
1.1.1 History of oncolytic viruses  
Oncolytic viruses (OVs) are a class of virus that preferentially infect cancer 
cells, inducing cancer cell lysis via immune stimulation. The idea of using OVs as an 
anti-cancer agent originated in the mid-19th century, when several cases reports revealed 
viral infection coincidentally led to tumor remission.1-4 Later on, similar incidents were 
observed as tumors on patients regressed coincident with viral infections such as hepatitis, 
glandular fever, and measles. These caused researchers to note the potential oncolytic 
nature of viruses. In most cases, however, naturally developed viral infections weakened 
tumor growth very briefly and insufficiently.  
The beginning of the 20th century brought sporadic attempts to utilize viruses 
therapeutically.4 Hepatitis B virus was one of the first used in clinical cancer therapy. In 
1949, a clinical trial was conducted in which 22 patients with Hodgkin’s disease were 
treated with tissue extracts, or injected with unpurified human serum containing hepatitis 
virus.5 Results showed that 14 out of 22 patients developed hepatitis. Seven out of 22 
patients showed improvement in clinical aspects of disease and 4 showed a reduction in 
tumor size.5 Although many of the patients suffered from side effects of viral infection, 
with one patient death confirmed, the results were still encouraging at the time, as the 
fate of patients afflicted with cancer was desperate at that time. A few years later, clinical 
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trials using glandular fever serum as a treatment for acute leukemia were conducted, 
which achieved more encouraging results.6 Many other human pathogens were then 
administered to treat cancer patients in the following decades.4  
In the meantime, by building on established ex vivo tissue and cell culture 
systems, animal models of cancer were gradually developed through the mid-20th century. 
As a result, oncolytic viruses have since been tested using laboratory animals (mice and 
rodents in most cases) implanted with cancer. Many of these experiments were highly 
encouraging, with complete tumor remission achieved,7,8 and researchers noted that 
oncolytic viruses tended to have higher efficacy in animal models compared to the 
patients.9-11  
The idea of using non-human viruses to treat cancer patients arose in the early 
1950s, as said viruses produced little pathology in humans while retaining their oncolytic 
potency towards cancer cells.8 Related studies have since been conducted, and several 
animal viruses were screened for oncolytic potential against human cancer cells.12,13 
Later clinical trials showed that some of animal viruses did not have enough therapeutic 
effect on human cancer.14 Some viruses failed in animal experiments, with the infection 
causing death to animals.7,9,15,16 Until today, several animal viruses such as Vesicular 
stomatitis virus (VSV) and Newcastle disease virus (NDV [which showed efficacy in 




Since the 1950s, researchers have been investigating ways to manipulate 
viruses in order to make them more oncolytic or to increase their tumor-specificity. 
Despite these efforts, there was little success in the field until the 1990s, when 
development of recombinant DNA technology made virus engineering possible. 
Researchers’ focus was then cast upon virus manipulation and viral genome engineering 
in order to build viruses which are safer, yet more aggressive and specific to cancer cells. 
In 2005, the first oncolytic virus H101, a genetically altered adenovirus, in combination 
with chemotherapy, was approved to treat nasopharyngeal carcinoma in China.17 
In 2015, talimogene laherparepvec (T‑VEC), a genetically modified herpes 
simplex virus type 1 (HSV-1), became the first OV approved by the Food and Drug 
Administration (FDA) in the United States, which is a landmark in the field.18 Today, a 
wide range of viruses are under clinical investigation, including viruses with nonhuman 
hosts such as VSV, and NDV; many well understood or easily engineered human viruses 
like Adenovirus, Herpes simplex virus, Measles virus, Poliovirus, Vaccinia virus and 






1.1.2 Molecular mechanism of oncolytic viruses  
OVs take advantage of aberrant molecular changes in cancer cells to facilitate 
their replication. In normal cells, different molecular signaling pathways are exploited in 
antiviral defense. When infected by viruses, cells release interferons (IFNs) which 
triggers the activation of the JAK-STAT (Janus kinase–signal transducer and activator of 
transcription) pathway and the anti-viral machinery by inducing transcription of hundreds 
of anti-viral genes.19 Briefly, IFNs bind to their cognate receptors and this further 
activates Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). These two kinases 
phosphorylate the IFN receptor chains, which recruits the STAT proteins and induce their 
phosphorylation and dimerization. The dimerized STAT proteins together with IFN 
regulatory factor 9 (IRF9) form interferon stimulated gene factor 3 (ISGF3) complex. 
Next, the complex translocates into nucleus and binds to IFN-stimulated response 
element (ISRE) to stimulate antiviral gene expression. It should be noted, however, 
cancer cells are generally insensitive to IFNs, thus anti-viral defense via IFN stimulation 
is impeded,20 allowing viruses to proliferate in cancer cells. 
Ras is a small GTPase that plays an important role in regulating cell 
proliferation.21 The aberrant regulation of Ras is a common trait in many types of cancer. 
It has been widely noted that the activated Ras signaling pathway is one of the major 
mechanisms for viral oncolysis.22-26 Several mechanisms underlying Ras-dependent viral 
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oncolysis have been identified.27-29 Ras signaling pathway activation in cancer cells 
causes the cells to undergo increased proliferation, subsequently leading to more protein 
production, which is beneficial for more efficient viral replication.30 In addition, 
activation of Ras can inhibit the function of anti-viral protein kinase R, further supporting 
production of viral particles.27 Ras signaling is also considered to be a negative regulator 
of IFN signaling.31,32 The Hirasawa lab demonstrated that activation of the 
Ras-Raf-mitogen-activated protein kinase kinase (MEK)-mitogen-activated protein 
kinase kinase (ERK) pathway can inhibit host anti-viral response induced by type I 
IFNs.33,34 The inhibition has been further illustrated to be caused by Ras/MEK 
downregulation of a group of IFN-mediated antiviral genes, through negatively 
regulating interferon regulatory factor 1 (IRF1), a transcription factor for these genes 
(Figure 1).35-37 Thus, IRF1 is considered a key protein that links Ras activation with IFN 
insensitivity in molecular mechanisms underlying viral oncolysis. 
P53 deficiency is also a feature of cancer cells exploited by oncolytic viruses. 
The tumor suppressor protein p53 has been named the ‘guardian of the genome’ as it can 
activate the transcription of its responsive genes to induce cell apoptosis, cell cycle arrest 
or DNA repair upon genomic stress.38 Certain viruses are prone to infect cancer cells with 




Figure 1. Connection between Ras activation and IFN insensitivity in viral oncolysis  
Ras-MEK-ERK pathway inhibits type I IFNs-induced anti-viral genes through 

































1.2 IRF1  
Interferon regulatory factor 1 (IRF1) was the first member of the interferon 
regulatory factor (IRF) family identified as a transcription activator for type I 
interferon.41 The IRF family is a group of transcription regulators, of which nine 
members were found in humans. They have highly conserved DNA-binding domains 
(DBDs) in their N-terminus, forming a helix-turn-helix structure.42 IRFs bind to promoter 
regions of target genes to regulate gene transcription,43 either to the IRF-binding element 
(IRF-E), or to the interferon-sensitive response element (ISRE). 
IRF1 plays a crucial role in anti-viral immune response. Viral infections, 
including Newcastle disease virus, Encephalomyocarditid virus and VSV, induce type I 
IFN genes in most cell types.44,45 IRF1 is involved in activating type I IFN genes during 
viral infection, although their induction is not dependent only on IRF1.46 The Toll-like 
receptor 9 (TLR9)/MyD88/IRF1/IFN-β pathway is one of the IRF1-mediated signaling 
cascades, which has been shown to have potent anti-viral properties in vitro and in vivo.47 
In addition, IFN-γ, which is the only member of the type II class of interferons, is 
involved in the TLR9/MyD88/IRF1/IFN-β pathway as it induces activation and 
translocation of IRF1 from cytoplasm to nucleus.48 IRF1 interacts with nuclear factor 
κ-light-chain-enhancer of activated B cells (NF-κB) upon stimulation with IFN-γ and 
tumor necrosis factor-α (TNF-α) induced by herpes simplex virus infection, mediating 
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production of nitric oxide (NO) by promoting the transcription of inducible nitric oxide 
synthase (iNOS).49 This innate immunity is important to the host, as the production of 
NO is essential for defending against bacteria, viruses, tumor cells and other pathogens. 
IRF1 also plays essential roles in the development of immune cells, and influences 
differentiation of natural killer (NK) cells.50 Moreover, IRF1 is required for the 
differentiation of T helper 1 cells, as shown by absence of T helper 1 differentiation in in 
vivo IRF1-/- mouse system.51  
Furthermore, IRF1 demonstrates anti-tumor functions. IRF1 alleles are often 
singly or completely lost in different types of cancers, such as leukemia, esophageal 
cancer and gastric cancer.52-54 IRF1 inactivation can also be caused by aberrant splicing 
of the gene or the binding of nucleophosmin to IRF1, which prohibits its DNA binding 
ability.55,56 IRF1 has also been shown to have anti-tumor growth effects in in vivo 
experimental system.57 Notably, IRF1 activates transcription of tumor suppressor genes, 
genes regulating cell cycle arrest and/or programmed cell death (which cause cancer cell 
death).58-63 IRF1 also induces transcription of anti-proliferative genes such as 
p21WAF1/CIP1 and p53.58,62 IRF1 can be considered a potential biomarker due to its 
anti-tumor properties as well as its ability to elevate neoadjuvant radio/chemotherapy 
responses in cervical cancer.64   
IRF1 function is not only regulated at the transcriptional level but also at 
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posttranscriptional and/or posttranslational levels. Several micro RNAs (miRs) have been 
shown to regulate IRF1 expression, such as miR-23a, miR-383 and miR-132a-3p.65-67 
Posttranslational modifications (PTMs) have also been demonstrated to be crucial for 
IRF1 regulation.68 Commonly found types of PTMs for IRF1 are acetylation, 
phosphorylation, ubiquitination and sumoylation. P300 regulates IRF1 acetylation, 
increasing DNA binding ability and transcriptional activity of IRF1.69 IRF1 
phosphorylation by Casein kinase II is also important in maintaining its transactivation 
function.70 In contrast, inhibitor of NF-κB kinase ε was reported to phosphorylate IRF-1 
in primary CD4+ T cells, which inhibits its transcriptional activity.71 IRF1 can be 
degraded by ubiquitin-mediated proteasome,72-74 an essential method for modulating 
IRF1 protein level. Furthermore, recent studies showed IRF1 phosphorylation initiates 
ubiquitination-mediated degradation, as well as transcriptional activation, which is a key 
component for its anti-proliferative activity in cancer cells.75 Sumoylation of IRF1 has 
generally been reported to inhibit its transcriptional activity.76,77 Interestingly, increased 







1.3 PIAS3  
Protein inhibitors of activated signal transducers and activators of transcription 
3 (PIAS3), which belongs to the protein inhibitor of activated STAT (PIAS) family, is a 
major cellular inhibitor of STAT3. The family consists of four members in mammalian 
cells, which include PIAS1, PIAS2, PIAS3 and PIAS4, sharing more than 40% sequence 
identity.79 PIAS orthologs were also identified in yeasts, plants and other nonvertebrate 
animals such as Drosophila.80-82 PIAS3 was first found as a homologue of PIAS1, as well 
as being a novel chaperone of specific K(+) channels.83,84 Considerable research has been 
conducted on PIAS proteins, elucidating that they play important roles in immune 
function, cytokine signaling and other forms of cellular regulation.79,85,86 
Five key structures of human PIAS proteins have been identified: the 
N-terminal scaffold attachment factor-A/B, ACINUS and PIAS (SAP) domain, the 
Pro-Ile-Asn-Ile-Thr (PINIT) motif, the Really Interesting New Gene (RING)-finger-like 
zinc-binding domain (RLD), the highly acidic (AD) region, and the C-terminal 
serine/threonine-rich (S/T) region (Figure 2).87 The RLD and SAP domain are the most 
conserved among PIAS proteins, and the SAP domain is usually found in chromatin 
binding proteins.88 Nuclear magnetic resonance analysis revealed that the SAP domain of 
PIAS1 has DNA binding capability.89 The featured LXXLL motif (X represents any 
amino acid) was characterized within the SAP domain of PIAS proteins, and is a motif 
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responsible for the interplay of nuclear receptors and their co-regulators.90 RLDs of PIAS 
proteins are required for their small ubiquitin-like modifier (SUMO)-E3-ligase activity,91 
while the genuine RING domains are often present in ubiquitin E3 ligases.92 The PINIT 
motif is highly conserved within the PIAS family, being responsible for the subcellular 
localization of PIAS3.93 A region with 51 amino acids in PINIT motif was shown to be an 
inhibitory domain for both microphthalmia-associated transcription factor (MITF) and 
STAT3.94-97 AD located close to the C-terminus is also conserved among PIAS proteins. 
A putative SUMO interaction motif (SIM) was found within AD for most PIAS proteins 
including PIAS3.86 SIMs interact non-covalently with SUMO proteins, and are also 
found in many nuclear proteins reportedly involved in sumoylation.85 The S/T region of 
the C-terminus is highly variant among PIAS proteins but was still found in all PIAS 
proteins except for PIAS4. The functional feature of S/T region remains to be defined. 
Two PIAS3 isoforms, PIAS3 and PIAS3β, have been identified. PIAS3β has an insertion 
of 39 amino-acid residues in between the SAP domain and PINIT domain.79 
PIAS proteins are known for their roles as SUMO E3 ligases. In the process of 
sumoylation, inactive SUMO precursors of either SUMO1, SUMO2, or SUMO3 are 
cleaved and activated in an ATP-dependent manner by SUMO E1 activating enzyme, 
which is a heterodimer composed of SUMO-activating enzyme subunit (SAE) 1 and 
SAE2 in humans.98 Next, SUMO molecules are transferred from the E1 enzyme to the 
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SUMO E2 conjugating enzyme called ubiquitin carrier protein 9 (Ubc9). Finally, with 
assistance of a SUMO E3 ligase, SUMO is transferred from the E2 enzyme to the lysine 
residue of the substrate. It should be noted that E3 ligases are not mandatory for 
sumoylation, as Ubc9 itself can mediate transfer of SUMO to substrate target proteins 
without E3 ligase interaction in some cases.99 Nevertheless, SUMO E3 ligases help 
stabilize the substrate-E2-SUMO complex, which promotes the efficiency of SUMO 
transfer.100 So far, ten different proteins have been identified to have SUMO-E3-ligase 
activity in humans, including the PIAS family, Ran binding protein 2 (RanBP2), and the 
zinc finger protein 451 (ZNF451) family.99 While it was originally believed that each E3 
enzyme was specific to some substrates, considering there are thousands of sumoylation 
substrates and only ten identified E3 ligases, the notion that E3 ligases determine 
substrate specificity is controversial at best.99 More studies should be conducted to 
identify how SUMO E3 ligases conduct substrate specific sumoylation. 
PIAS3 and other PIAS proteins can facilitate a variety of functions in cellular 
regulation. PIAS proteins interact with more than 60 proteins, a large portion of which 
are transcription factors.87 These interactions can either repress or promote their 
transcription functions. The regulatory mechanisms vary, but are highly dependent on the 
SUMO-E3-ligase activity within PIAS, or at least on their ability to facilitate SUMO 
modification.85 One example of how PIAS3 regulates cellular functions is its direct 
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interaction and promotion of sumoylation within nuclear receptor subfamily 2, group E, 
member 3 (Nr2e3), resulting in conversion of Nr2e3 to a transcriptional repressor of the 
photoreceptor-specific genes.101 Moreover, PIAS3 promotes transcriptional responses of 
transforming growth factor-β (TGF-β)/Smad signalling by interacting with 
p300/cAMP-response element binding protein-binding protein (CBP), the transcriptional 
coactivator. The RLD of PIAS3 is essential for the interaction with p300/CBP.102 PIAS3 
also directly associates with the p65 subunit of NF-κB and suppresses its transcriptional 
activity. For this interaction, the N-terminal LXXLL motif of PIAS3 is required.103 
PIAS1 has also been reported to negatively regulate NF-κB signaling by blocking DNA 
binding activity towards the downstream genes.104 Although PIAS3 and PIAS1 perform 
as SUMO E3 ligases for the estrogen receptor α (ERα), PIAS1 regulates ERα 
transcriptional function independently of its SUMO E3 ligase function, as the PIAS1 
mutant that lacks E3 ligase activity could still regulate the transcriptional function of 
ERα.105 Furthermore, the binding of PIAS3 to STAT3 physically inhibits the DNA 
binding activity of STAT3 and stops transcriptional activation of STAT3-mediated 
genes.83 Through interacting with STAT3 (a key regulator of the immune response) 
PIAS3 is involved in immune regulation.87 Similarly, PIAS1 impairs transcriptional 
activity of STAT1 in the same way.83 Apart from these, PIAS4 functions as SUMO E3 
ligase to stimulate the sumoylation and transcriptional activity of p53.106 PIAS1 and 
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PIASxα are reported to interact functionally with the glucocorticoid receptor-interacting 




















Figure 2. Schematic domain structure of PIAS3  



























































The regulation of Ras/MEK on IRF1 is an important cellular mechanism for 
viral oncolysis. In a previous work, we demonstrated that Ras/MEK does not 
down-regulate IRF1 at the transcriptional level.108 Considering that IRF1 is dramatically 
modulated by posttranslational modifications, I hypothesized that PTMs of IRF1 by 
Ras/MEK could be essential to determine cellular sensitivity to oncolytic viruses in 
cancer cells. PIAS3 is a key regulator as a SUMO E3 ligase for many transcription 
factors including IRF1.77 The objectives of my MSc project were as follows: 
1) Determine if PIAS3 directly interacts with IRF1. 
2) If this is the case, determine if the Ras/MEK pathway regulates the interaction 
between IRF1 and PIAS3.  






























3.1 Cells and Viruses 
Human fibrosarcoma cells (HT1080) were obtained from the American Type 
Culture Collection (Manassas, VA, USA). VSV (Indiana strain) was provided by Dr. John 
C. Bell (Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, 
Ottawa, Canada). The VSVs were amplified and titrated by plaque assay using the mouse 
fibroblast cell line L929 cells.  
 
3.2 Cell culture 
The cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium 
(Multicell, Wisent Inc., QC, Canada) with 10% fetal bovine serum (GE Healthcare Life 
Sciences, Illinois), 1 mM sodium pyruvate (Life Technologies LTD, UK) and 
antibiotic-antimycotic (Thermo Fisher Scientific, Massachusetts). Cells were maintained 
in 10-cm culture dishes at 37℃ with 5% CO2 for the use of experiments in this project. 
Cells were subcultured three times a week on average. For subculture, 0.25% 
trypsin-EDTA (Life Technologies LTD) was used to detach cells. 
 
3.3 Generation of CRISPR (clustered regularly interspaced short palindromic repeats) 
knockdown clones  
The PIAS3 CRISPR clones were generated by Ysabel Meneses, another 
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graduate student in the Hirasawa lab. PSpCas9-2A-GFP plasmid (purchased from 
Addgene, Massachusetts) was digested and ligated with sgRNA targeting PIAS3 gene 
(sense 5’-CAC CGA GTG CGC TTC CTC AAA CCG C - 3’, anti-sense 5’- AAA CGC 
GGT TTG AGG AAG CGC ACT C- 3’). After validation, the newly-generated plasmid 
was transfected into HT1080 cells. Twenty-four hours post transfection, cells were 
subjected to fluorescence-activated cell sorting (FACS) with the Beckman Coulter MoFlo 
Astrios EQ Cell Sorter (Beckman Coulter, CA) to select green fluorescent protein (GFP) 
positive cells. To obtain CRISPR single cell clones, GFP-positive cells were collected, 
and a limiting dilution series was conducted in a 96-well plate. For the dilution, 4,000 
cells were plated in the first well of the first column (8 rows and 12 columns in a 96-well 
plate). Then, half of the cells in the first well were transferred into the second well of the 
same column. The 1/2 dilution was repeated down the entire 8 rows of the first column. 
Next, half of the cells in the wells of the first column were transferred into the 
corresponding wells in the second column of the plate. The 1/2 dilution was repeated 
down the entire 12 columns. Formation of colonies from single cells was monitored daily 
and appearance of GFP-positive cells was checked under fluorescent microscope 
regularly. The wells with GFP-positive single colonies were marked. The cells were 
grown to full confluence, and then transferred into 24-well plates. When the cloned cells 
grew to full confluency in the 24-well plates, they were collected and the PIAS3 
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expression levels of these clones were assessed by western blot analysis conducted by 
Danyang Xu. The CRISPR clone 1, clone 3 and clone 6 were also amplified and frozen 
for later use. 
 
3.4 Western Blot Analysis  
Cells were washed with phosphate-buffered saline (PBS) buffer. Then total cell 
protein in each well of a 24-well plate was collected with 100 μL 
radioimmunoprecipitation assay (RIPA) buffer with phenylmethylsulfonyl fluoride 
(PMSF) (Sigma-Aldrich, Missouri), aprotinin (Sigma-Aldrich) and phosphatase 
inhibitors (halt phosphatase inhibitor cocktail, Thermo Fisher Scientific). Fifty μL sample 
buffer ( 188 mM Tris–HCl (pH 6.8), 6% sodium dodecyl sulfate, 0.3% bromophenol blue, 
30% glycerol, 15% β-mercaptoethanol ) was added into each sample and they were 
boiled for 5 minutes. Ten μL of each sample was subjected to 10% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gel was run with constant 
current of 20 mA. Proteins were then transferred to a 0.2 μm nitrocellulose membrane 
(Bio-Rad, ON, Canada) with Tran-blot Turbo Transfer System (Bio-Rad). The membrane 
was blocked with 5% skim milk in tris-buffered saline (TBS) with Tween 20 (TBS-T) for 
1 hour, and then blotted with primary antibodies in conditions shown in table 1 for 
overnight at 4 °C. The following day, membranes were washed three times with TBS-T, 5 
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minutes for each. Membranes were blotted with corresponding secondary antibody 
(conditions shown in table 1) for 1 hour at room temperature followed by three washes in 
TBS-T. Specific bands were detected with ImageQuant LAS 4000 (GE Healthcare Life 
Sciences, QC, Canada) using chemiluminescence substrate (Bio-Rad), and analyzed with 
ImageQuant Software (GE Healthcare Life Sciences). 
 
3.5 Immunoprecipitation 
HT1080 cells were plated into 10-cm culture dishes. When cells were about 70 % 
confluent, they were co-transfected with 5 μg pcDNA3.1 empty vector plasmid, 
pcDNA3.1-IRF1 plasmid and pcDNA3.1-FLAG-PIAS3 plasmid using Superfect 
Transfection Reagent (Qiagen, ON, Canada) according to manufacturer’s instruction. 24 
hours after transfection, cells co-transfected with pcDNA3.1-IRF1 and 
pcDNA3.1-FLAG-PIAS3 plasmid were treated with 20 μM U0126 (Cell Signalling 
Technology, Danvers, MA) or the same volume of dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich) for 6 hours. U0126 is a highly selective inhibitor for both MEK1 and 
MEK2, that blocks the phosphorylation activity of MEKs towards ERKs.109,110 Four 
hours after U0126 treatment, 25 μM MG132 (Sigma-Aldrich) was added to prevent 
protein degradation. After treatment, cells were washed twice with ice-cold PBS, then 
lysed with 1 mL 1 % TritonX-100 lysis buffer (20mM TrisHCl pH8, 1% TritonX-100, 10% 
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glycerol, 2mM EDTA, 137 mM NaCl) which was supplemented with protease inhibitors 
PMSF (Sigma-Aldrich, Missouri), aprotinin (Sigma-Aldrich), halt phosphatase inhibitor 
cocktail (Thermo Fisher Scientific), and 20 μM desumoylation inhibitor 
N-ethylmaleimide (Sigma-Aldrich). The cell lysate was centrifuged at 14,000 rpm for 10 
minutes at 4 °C. The supernatant was pre-cleared for 1 hour using 30 μl of 
pre-equilibrated protein A agarose beads (Thermo Fisher Scientific), then 
immunoprecipitated with 2 μg mouse anti-IRF1 antibody (BD biosciences), or mouse 
anti-Flag M2 antibody (Sigma-Aldrich) overnight at 4 °C. The next day, cell lysate with 
antibody was incubated with 30 μl pre-blocked protein A agarose beads for 2 hours at 
4 °C. After incubation, the complex was centrifuged at 5000 rpm for 1 minute at 4 °C. 
The supernatant was discarded, and the precipitated beads were washed three times with 
1 mL 1 % TritonX-100 lysis buffer. Proteins were eluted by boiling the beads in 1x 
sample buffer as described previously for 10 minutes. Samples were subjected to 
SDS-PAGE, followed by western blot analysis using the IRF1, PIAS3 and β-Actin 
antibodies listed in table 1. 
 
3.6 Quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
RNA was isolated from HT1080 parental cells and HT1080 PIAS3 knockdown 
clone 1, clone 3 and clone 6 cells. cDNA was synthesized from the RNA using the 
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RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, 
Massachusetts). Quantitative PCR (qPCR) was performed in triplicate using 
powerSYBR®Green PCR Master Mix (Life Technologies LTD, UK ) to detect Guanylate 
Binding Protein 2 (GBP2), Interferon Induced Protein with Tetratricopeptide Repeats 2 
(IFIT2), Microtubule-associated Protein (MAP2), signal transducers and activators of 
transcription 2 (STAT2), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
levels and analyzed with StepOnePlus qPCR system (Applied Biosystems, CA). The 
polymerase chain reaction (PCR) procedure was as manufacturer’s instructions: 95°C for 
10 min followed by 40 cycles of 95°C for 15 sec, 60°C for 1 min, and then followed by 
melt-curve analysis. For data analysis and statistical analysis, the GBP2, IFIT2, MAP2 
and STAT2 mRNA levels of each sample was normalized to GAPDH. Then fold change 
of each sample toward the parental cells sample was calculated. The One-way analysis of 
variance (ANOVA) with Tukey’s post-hoc test was performed using GraphPad Prism 6.0 
software (GraphPad Software, CA). Sequence for all primers used is listed in table 2.  
 
3.7 Virus Infection 
HT1080 cells and PIAS3 CRISPR clone 1, 3 and 6 cells were plated the day 
before infection. When cells reached about 80 % confluency, they were subjected to VSV 
infection (multiplicity of infection (MOI) = 1/4, 1/8, 1/16, 1/32 and 1/64) for 16 hours. 
28 
 
Cells were then lysed, followed by western blot analysis for detection of virus protein. 
Table 1. Primary and secondary antibody conditions for western blot 
Antibody Primary antibody 
condition 





1:1000 in 5 % milk 1:5000 Anti-mouse IgG in 5 % 
milk 








1:10,000 in 5 % milk 













Table 2. qPCR primers 
Gene 
Name 
5’ Primer 3’ Primer 
GAPDH ATCTTCTTTTGCGTCGCCAG ACGACCAAATCCGTTGACTCC 
GBP2 TTTCACCCTGGAACTGGAAG TGCACAACCGAGGATCATTA 
IFIT2 ATTGCACTGCAACCATGAGTG TCCCTCCATCAAGTTCCAGGT 
MAP2 CCATTTGCAACAGGAAGACAC CAGCTCAAATGCTTTGCAACTAT 

































4.1 IRF1 does not have direct interaction with PIAS3 
To determine if IRF1 interacts with PIAS3, a co-immunoprecipitation (co-IP) 
experiment was conducted using HT080 cells. I also determined if MEK inhibition 
modulates the interaction between IRF1 and PIAS3. Cells were transfected with 
pcDNA3.1-IRF1 plasmid and/or pcDNA3.1-Flag-PIAS3 plasmid. At 18 hours after 
transfection, the cells were treated with U0126 (20 μM) or the same volume of DMSO 
for 6 hours. At 22 hours after transfection, the proteasome inhibitor, MG132 treatment 
(25 μM) was added for 2 hours to prevent protein degradation. At 24 hours after 
transfection, cells lysates were prepared for immunoprecipitation with either anti-Flag 
antibodies or anti-IRF1 antibodies, followed by western blot analysis. As shown in 
Figure 3, the cells effectively express IRF1 or PIAS3 (input) indicating that the 
transfection was successfully performed. I also detected PIAS3 protein in samples 
immunoprecipitated with anti-PIAS3 antibody (Figure 3A) as well as IRF1 protein in 
immunoprecipitation with anti-IRF1 antibody (Figure 3B). These results suggest that the 
immunoprecipitation successfully pull-downed the target proteins. However, IRF1 was 
not detected in the PIAS3-pulldown samples. Similarly, PIAS3 was not detected with the 
IRF1-pulldown samples, indicating that IRF1 and PIAS3 do not have close interaction in 




Figure 3. Identification of interaction between IRF1 and PIAS3 in HT1080 cells 
Co-immunoprecipitation (Co-IP) assay was conducted with HT1080 cells overexpressed 
with IRF1 and/or Flag tagged PIAS3 treated with or without U0126. Total cell lysates 
were subjected to immunoprecipitation (IP) with antibodies against Flag (A) or 
antibodies against IRF1 (B), followed by western blot analysis with anti-IFR1 antibodies 
as well as anti-PIAS3 antibodies to detect IRF1 and Flag tagged PIAS3. Data here are 2 

























4.2 IRF1 expression is increased in response to PIAS3 knowckdown 
To further determine the role of PIAS3 on IRF1 regulation, we decided to 
establish PIAS3 knockdown HT1080 cells. As mentioned in chapter 3, PIAS3 was 
knocked down via CRISPR-Cas9 technique. After screening more than 20 clones, three 
clones showed less PIAS3 expression compared with parental cells (Figure 4). When the 
levels of IRF1 expression were examined in the PIAS3 knockdown HT1080 cells, I 
found that PIAS3 CRISPR knockdown increased IRF1 levels compared to that in the 
parental control. The increase of IRF1 in PIAS3 clone 6 was not as clear as that in the 
other two clones. Nonetheless, considering less amount of the loading control (β-actin) in 
PIAS clone 6 compared to in control, the IRF1 level is higher. This result suggests that 
PIAS3 regulates IRF1 expression (Figure 4) while I did not confirm their direct 










Figure 4. IRF1 expression levels in PIAS3 CRISPRR knockdown clones 
Expression levels of PIAS3 and IRF1 in PIAS CRISPR-knockdown clones (PIAS3 clone 
1, clone 3 and clone 6) were determined by western blot, with β-Actin as a loading 







































4.3 PIAS3 knockdown increases transcription levels of some IRF1-mediated anti-viral 
genes 
As PIAS3 knockdown increases IRF1 expression level, we wanted to identify 
whether this could further modulate the function of IRF1 as a transcriptional regulator. 
Therefore, we conducted qRT-PCR to detect transcriptional levels of IRF1-mediated 
antiviral genes including GBP2, IFIT2, MAP2 and STAT2 in HT1080 parental and 
PIAS3 CRISPR knockdown cells. As is shown in Figure 5, all three PIAS3 CRISPR 
clones display significantly increased transcription of GBP2 compared to control cells. 
PIAS3 clone 1 and clone 6 showed significantly increased expression of MAP2 while 
PIAS clone 3 demonstrated a significant increase in IFIT2 expression level. There was no 
difference in STAT2 transcription level among parental cells and the PIAS CRISPR 
clones. The results of qRT-PCR demonstrate PIAS3 knockdown increases transcription 










Figure 5. Changes in transcriptional level of certain IRF1-mediated antiviral genes 
by PIAS3 knockout  
The gene transcriptional level of GBP2, IFIT2, MAP2 and STAT2 in HT1080 parental 
cells, PIAS3 CRISPR-knockout clone1, clone 3 or clone 6 were determined by 
quantitative RT-PCR. The relative quantification (RQ) of transcriptional level was 
calculated by normalizing to GAPDH expression levels and then divided by that of the 




































































































































































4.4 PIAS3 knockdown does not increase cellular resistance to virus infection 
As IRF1 expression increased in response to PIAS3 knockdown, resulting in 
increased expression of the antiviral proteins, we wanted to identify if this could have 
any effects on cell susceptibility towards virus infection. To test this possibility, the 
PIAS3 CRISPR clones along with HT1080 parental cells were subjected to VSV 
infection with different MOIs (MOI=1/4, 1/8, 1/16, 1/32 and 1/64) for 16 hours. Cells 
were lysed for western blot analysis to detect intracellular viral proteins. PIAS3 CRISPR 
clone 3 cells were resistant to virus infection compared with the parental control 
throughout different MOIs, as less virus protein was detected (Figure 6). However, 
PIAS3 CRISPR clone 1 and clone 6 cells were more susceptible to virus infection 
compared with the control cells with higher MOI (MOI = 1/4, 1/8, 1/16, 1/32) as more 
virus protein was detected in these two clones than in the parental cells. As the sensitivity 
to VSV infection was not consistent amongst the three PIAS3 CRISPR clones, the results 
are not conclusive. However, the results suggest that PIAS3 knockdown is not sufficient 
to increase cellular resistance to virus infection because two of the three PIAS3 CRISPR 






Figure 6. Determination of cell susceptibility of PIAS3 CRISPR knockout clones 
towards VSV infection  
HT1080 parental cells as control and PIAS3 knockout cells (PIAS3 clone 1, clone3 and 
clone 6) were infected with VSV (MOI=0, 1/4, 1/8, 1/16, 1/32 or 1/64) for 16 hours. 
Western blot analysis was conducted to detect virus protein (VSV-G). β-Actin was used 
as a loading control here. Data here are representative of 2 independent experiments. 















































In summary of the results, IRF1 does not have direct interaction with PIAS3 in 
HT1080 cells while PIAS3 regulates IRF1 expression. Moreover, knockdown of PIAS3 
increases transcription levels of IRF1-mediated anti-viral genes but is not sufficient to 
increase cellular resistance to virus infection.  
A direct interaction between PIAS3 and IRF1 was expected as PIAS3 has been 
reported to be a SUMO E3 ligase of IRF1 by Nakagawa and Yokosawa.77 In their study, 
they were able to detect the binding of the two proteins using immunoprecipitation in 
293T cells where FLAG-tagged IRF1 and myc-tagged PIAS3 were co-transfected. The 
cellular signalling environment varies for different cell lines, which could be the reason 
for the inconsistency with the previous study as we used HT1080 cells. In addition, more 
than one PIAS proteins could bind to IRF1 and promote its sumoylation.111 Therefore, it 
is possible that other proteins than PIAS3 serve as SUMO E3 ligase(s) for IRF1 in 
HT1080 cells, which could be why we did not detect the direct interaction between 
PIAS3 and IRF1 in our system. PIAS3 binds to IRF1 to promote SUMO1-mediated 
sumoylation of IRF1 in 293T cells. In HT1080, we were not able to detect high 
sumoylation level of IRF1 without overexpressing SUMO proteins together with IRF1 
(data not shown). This indicates that the SUMO pathway mediated by PIAS3 is not very 
active in HT1080 cells. This could be another possible explanation why we did not detect 
the direct interaction. To answer this, we would overexpress other elements of the SUMO 
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pathway such as the SUMO E2 conjugating enzyme Ubc9 to confirm the interaction of 
IRF1 and PIAS3 in HT1080.  
Two bands of IRF1 were observed in HT1080 control cells (Figure 4 lane 1). 
However, when PIAS3 was knocked down by CRISPR, the lower band increased its 
intensity while the upper band was not detected (Figure 4 lane 2 and 3). This may suggest 
that PIAS3 knockdown blocked posttranslational modifications of IRF1 (upper band) and 
increased expression of non-modified IRF1 (lower band). However, the upper band of 
IRF1 in HT1080 control cells was not always shown or consistent in experiments we 
conducted. We assume that this could be due to the lot-to-lot difference of antibodies or 
sample preparation. To further study this, we will need to test different IRF1 antibodies 
and different lysis buffers specially containing proteasome inhibitors.    
Although we were not able to detect direct interaction between IRF1 and 
PIAS3, PIAS3 modulates IRF1 expression and its transcriptional functions. Increased 
expression of IRF1 was observed in all the three PIAS3 CRISPR knockdown clones of 
HT1080 cells. However, these clones showed different expression profiles of the IRF1 
mediated anti-viral genes. For GBP2, all three clones have increased expression 
compared with the control cell. Clone 3, but not clone 1 or 6, showed significantly higher 
expression of IFIT2 than the parental cells while this was completely opposite for MAP2. 
The CRISPR clones were derived from single positive cell colonies or very few cells 
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after FACS sorting following transfection of the CRISPR plasmid into HT1080 cells. We 
would expect molecular variations in different clones as the gene expression background 
of each single cell varies even though they originated from the same cell line. To reach a 
clear conclusion, we will need to conduct RNA sequencing to obtain global changes in 
transcription of IRF1-mediated antiviral genes caused by PIAS3 knockdown.  
There are weakness and limitations in the methodology and experimental 
design of my thesis. When I conducted the immunoprecipitation analysis with cell lysates 
treated with the MEK inhibitor (Figure 3), I did not conduct western blot analysis for 
phosphorylated ERKs to confirm if the MEK inhibitor inhibits the pathway. Although 
this did not change our conclusion as there was no direct interaction detected between 
IRF1 and PIAS3, it should have been included in Figure 3. Second, it was not optimal to 
use HT1080 parental cells as a control of the PIAS3 CRISPR clones because the parental 
cells are pooled cells while the CRISPR clones are from single cells. However, it was not 
technically possible to have the same single cell to generate both control and CRISPR 
knockout clones. Alternatively, we could have all the GFP positive cells collected after 
FACS sorting following transfection of the PIAS3 CRISPR plasmid. In this case, the 
effects of PIAS3 knockdown on the antiviral transcription as pooled cells, which are 
comparative to parental HT1080 cells. We assume that this approach is more feasible 
than the approaches we used. At last, even though efforts were made to get single cell 
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when generating PIAS3 knockdown clones including doing limiting dilution and 
checking under microscope (Chapter 3 part 3), it is still not guaranteed that the three 
clones were absolutely generated from single cells. Whereas, PIAS3 knockdown was 
consistent in the three clones while these experiments were being conducted, which 
shows that this technical limitation would hardly affect the results of my experiments 
regarding the three PIAS3 clones. 
There was an intensive band below endogenous PIAS3 protein on anti-PIAS3 
western blot analysis of PIAS3 CRISPR clone 3, which was not observed in PIAS3 
CRISPR clone 1 and clone 6 (Figure 4). Total human PIAS3 protein is comprised of 619 
amino acids, which should be around 68 kDa. The lower band of the clone 3 can either be 
a nonspecific band or aberrant protein isoform of PIAS3. As I repeated the experiment 
several times and always found the lower band in clone 3, but not in clone 1 or 6, it is not 
likely that it is a non-specific band. Interestingly, the expression profiles of 
IRF1-mediated antiviral genes (IFIT2 and MAP2) were different in clone 3 from clone 1 
and clone 6 (Figure 5), which suggests possible involvement of the protein in regulating 
the transcription of IRF1-mediated antiviral genes. If it is an aberrant isoform of PIAS3, 
it would be a novel regulator of IRF1 which functions in the absence of PIAS3. Then this 
could further shed light on the interplay between PIAS3 and IRF1.  
The PIAS3 knockdown did not increase cellular resistance to virus infection 
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(Figure 6). This might be because the changes of the IRF1-mediated antiviral 
transcription were not enough to increase cellular defense towards virus infection. While 
the expression of GBP2 (less than 2 folds) and MAP2 (10 folds) was significantly 
increased in PIAS3 CRISPR clone 1 and clone 6, the other antiviral genes, IFIT2 and 
STAT2, showed no difference. Here again, global gene expression analysis using RNA 
sequencing will help us to better understand how much antiviral transcription is 
modulated by the PIAS3 knockout.  
Altogether, we showed PIAS3 indirectly regulates IRF1 expression and 
transcriptional activities. Whereas, we did not elucidate cellular mechanisms of how 
PIAS3 regulates IRF1. We sought to detect the direct interaction between the two, yet, 
we did not find it in the cell line we tested. Although direct interactions are essential for 
protein sumoylation, it is still reasonable to consider that PIAS3 regulates IRF1 through 
promoting its sumoylation, presumably in an indirect way. To confirm this, I suggest 
conducting an in vitro sumoylation assay using IRF1 and PIAS3 in the future. Otherwise, 
it is also possible that PIAS3 indirectly modulates IRF1 through signaling pathways, as 
they both play parts in the JAK/STAT pathway.112,113 There might be an unidentified 
crosstalk between IRF1 and PIAS3 within JAK/STAT pathway. To identify the unknown 
connection, we will further conduct gain- and loss- of function experiments based on 
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